Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the most undervalued NASDAQ stocks to buy now. Piper Sandler reaffirmed its Overweight rating and $147 price target for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on September 15 in expectation of data from the upcoming clinical trial. Jazz is gearing up to report progression-free survival data from its HERIZON-GEA-01 study in the fourth quarter of 2025. The trial assesses zanidatamab as the first-line therapy for advanced/metastatic gastroesophageal adenocarc ...

Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing actionable trading ideas and well-researched investment recommendations. His insights have been featured in reputable publications such as The Axis business magazine and Investment Quarterly ...

Key Takeaways Epidiolex now drives over a quarter of Jazz's product sales and is on track for blockbuster status.Jazz balances growth with a strong oncology and neuroscience portfolio beyond cannabis therapies.Acquisition of Chimerix added Modeyso, its sixth oncology drug, after FDA approval for certain gliomas.JAZZ Pharmaceuticals (JAZZ) is not your typical cannabis stock involved in cultivation, processing, or sales of marijuana products. Instead, this commercial-stage biotech is the only one to market an ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Jazz Pharmaceuticals plc is one of them. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) continues to advance its mission to transform patient lives through innovative therapies for conditions with limited treatment options. The company’s marketed products lead in sleep medicine (Xywav, Xyrem), epilepsy (Epidiolex), and oncology (Zepzelca), while strategic acquisitions, including GW Pharmaceuticals and Chimerix ...

Accessibility StatementSkip Navigation 20 abstracts presented across World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine DUBLIN, Sept. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new real-world evidence and Phase 4 data reinforcing the value of Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution treatment outcomes in adults with narcolepsy or idiopathic hypersomnia (IH) were presented at World Sleep 2025, held in Singa ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to “most favored nation” (MFN) levels by September 29.President Trump’s demand for “binding commitments” to lower drug prices sent pharmaceutical companies “scrambling to respond,” according to a CNBC report on August ...

核心观点 - Jazz Pharmaceuticals plc (JAZZ) 入选12只廉价医疗股榜单并排名第九[1] - 公司核心业务聚焦肿瘤学、神经科学和睡眠医学领域创新疗法开发与商业化[1] - 获得FDA加速批准新型口服药物Modeyso用于治疗罕见儿科脑肿瘤[2][3] - 通过管线多元化和战略扩展强化神经科学与肿瘤学领域布局[3] 产品管线进展 - Modeyso (dordaviprone) 于2025年8月6日获FDA加速批准，成为首款针对1岁以上H3 K27M突变型弥漫性中线胶质瘤患者的疗法[2][3] - 该药物针对美国年患者数约2000人的罕见脑癌群体，临床数据显示22%总体缓解率（50例患者），中位缓解持续时间达10.3个月[2] - 73%应答者维持反应超过6个月，采用每周口服胶囊给药方式[2] - 继续批准取决于正在进行的三期ACTION验证性试验结果[2] 研发战略布局 - 神经科学领域：授权引进临床前阶段癫痫药物SAN2355以强化产品组合[3] - 肿瘤学领域：推进zanidatamab三期研究用于晚期胃食管癌，同时寻求Zepzelca作为广泛期小细胞肺癌一线治疗的监管批准[3] 市场定位 - 公司被列为低成本医疗保健投资标的，专注于满足未满足医疗需求的复杂疾病领域[1] - 全球生物制药领导者地位通过多元化管线建设和战略扩展得以强化[1][3]

公司动态 - 公司宣布其针对睡眠障碍治疗药物Xyrem的仿制药获得美国FDA批准 [2] - 公司通过简化新药申请（ANDA）获得市场准入资格 [2] 产品信息 - 获批仿制药对标爵士制药（JAZZ）的Xyrem睡眠障碍疗法 [2] 行业影响 - 仿制药获批将进入原研药Xyrem对应的睡眠障碍治疗市场 [2]

产品批准与商业化 - Jazz Pharmaceuticals旗下药物Modeyso（dordaviprone）获美国FDA加速批准 用于治疗1岁及以上复发或进展性H3 K27M突变型弥漫性中线胶质瘤患者 成为该罕见侵袭性脑瘤的首个治疗选择[1][2][9] - 美国国家综合癌症网络（NCCN）将Modeyso纳入临床实践指南 列为儿童及成人复发/进展性H3 K27M突变弥漫性高级别胶质瘤的2A类单药治疗方案 覆盖儿科中枢神经系统癌症和中枢神经系统癌症指南[1][3] 临床数据与疗效 - 基于5项开放标签临床研究中对50名患者的整合分析 Modeyso经盲态独立中心评审确认的总体缓解率（ORR）达22%（95% CI: 12-36） 中位缓解持续时间为10.3个月（95% CI: 7.3-15.2）[4] - 73%的应答者缓解持续时间超过6个月 27%超过12个月 试验采用神经肿瘤学反应评估（RANO 2.0）标准[4] 安全性特征 - 在376名胶质瘤患者的安全性评估中 33%出现严重不良反应 发生率超过2%的包括脑积水（5%）、呕吐（4.3%）、头痛（3.2%）、癫痫发作（2.4%）和肌无力（2.1%）[5][15] - 常见不良反应（发生率≥20%）包括疲劳（34%）、头痛（32%）、呕吐（24%）、恶心（24%）和肌肉骨骼疼痛（20%）[17] 药物机制与研发背景 - Modeyso为口服小分子药物 通过激活线粒体酪蛋白水解蛋白酶P（ClpP）并抑制多巴胺D2受体（DRD2） 在体外实验中可激活整合应激反应、诱导细胞凋亡并恢复H3 K27M突变胶质瘤的组蛋白三甲基化[7] - Jazz Pharmaceuticals于2025年4月收购Chimerix后获得该药物 目前仅在美国获批 全球其他地区尚未批准[8][9] 疾病背景与市场定位 - H3 K27M突变弥漫性中线胶质瘤是罕见高侵袭性脑瘤 患者中位生存期约1年 前线治疗后进展生存期不足6个月 主要影响儿童及青少年[5] - NCCN指南作为全球癌症治疗决策关键依据 涵盖医师、支付方及患者群体 此次快速纳入反映临床需求紧迫性[3] 后续开发要求 - FDA加速批准要求通过III期ACTION验证性试验（NCT05580562）确认临床获益 该试验正在评估Modeyso在新诊断H3 K27M突变胶质瘤患者放疗后的安全性与疗效[2][8]

公司业务进展 - 公司商业端和研发端均取得显著进展 特别在zanidatamab临床试验方面取得突破 [1] - 公司近期完成多项企业发展战略公告 显示积极的企业发展态势 [1] 管理层动态 - 高管Philip Johnson担任执行副总裁兼首席财务官 对加入团队决策表示满意 [1] - 管理层团队包括Bruce、Renee、Amal等核心成员 共同推动业务发展 [1] 投资者关系 - 公司积极参与投资者交流活动 会议现场气氛热烈 [1] - 高管与众多投资者进行会面 保持密切的投资者沟通 [1]